8-K: Allakos Inc. Faces Nasdaq Delisting Notice Due to Low Share Price

Allakos Inc. received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing its listing status at risk.

Summary

• Allakos Inc. received a notification from Nasdaq on August 13, 2024, stating that its stock price had fallen below the required $1.00 minimum for 30 consecutive business days between July 1, 2024, and August 12, 2024.
• The company has been granted a compliance period until February 10, 2025, to regain compliance by maintaining a share price of at least $1.00 for a minimum of ten consecutive business days.
• If Allakos fails to meet this requirement, it may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market, subject to meeting other listing requirements and paying a fee.
• To qualify for the second compliance period, the company would need to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for Nasdaq, with the exception of the bid price requirement.
• The company may need to implement a reverse stock split to regain compliance.
• There is no guarantee that Allakos will be eligible for the second compliance period or that Nasdaq will grant continued listing after a delisting notification.
• Allakos intends to monitor its stock price and evaluate options to regain compliance, but there is no assurance it will succeed.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. The risk of delisting is a significant concern for investors.

Positives

• Allakos has been granted a 180-day compliance period to regain compliance with Nasdaq's minimum bid price requirement.
• The company may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market.

Negatives

• Allakos's stock price has fallen below the minimum $1.00 threshold required for continued listing on the Nasdaq Global Select Market.
• There is no assurance that the company will be able to regain or maintain compliance with the minimum bid price requirement or any other Nasdaq listing standard.
• The company may need to implement a reverse stock split to regain compliance.

Risks

• There is a risk that Allakos will not be able to regain compliance with Nasdaq's minimum bid price requirement.
• The company may be delisted from the Nasdaq Global Select Market if it fails to regain compliance.
• The company's stock price may be negatively impacted by the delisting notice.
• There is no guarantee that the company will be eligible for the second compliance period.

Future Outlook

The company intends to actively monitor its stock price and evaluate options to resolve the deficiency and regain compliance with the minimum bid price requirement, but there is no assurance it will succeed.

Management Comments

• The Company intends to actively monitor the closing bid price of its shares of common stock during the Compliance Period and may, if appropriate, evaluate available options to resolve the deficiency and regain compliance with the minimum bid price requirement.
• While the Company is exercising diligent efforts to maintain the listing of its common stock on the Nasdaq Global Select Market, there can be no assurance that the Company will be able to regain or maintain compliance with the minimum bid price requirement or any other Nasdaq listing standard.

Industry Context

This announcement is not uncommon for companies that have experienced a significant decline in their stock price. It highlights the importance of maintaining a minimum share price to remain listed on major exchanges like Nasdaq.

Comparison to Industry Standards

• Many biotech companies, especially those in the clinical stage, face similar challenges with stock price volatility and the risk of delisting if they fail to meet minimum listing requirements.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have also faced similar delisting notices in the past, highlighting the competitive and volatile nature of the biotech sector.
• The Nasdaq minimum bid price rule is a standard requirement, and companies must actively manage their stock price to avoid delisting.

Stakeholder Impact

• Shareholders face the risk of potential delisting and a decline in the value of their investment.
• Employees may experience uncertainty about the company's future.
• Creditors may be concerned about the company's financial stability.

Next Steps

• Allakos will monitor its stock price during the compliance period.
• The company will evaluate options to regain compliance with the minimum bid price requirement.
• Allakos may need to submit a transfer application and pay a fee to transfer to the Nasdaq Capital Market.
• The company may need to implement a reverse stock split.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, compliance, stock price, reverse stock split, listing requirements, ALLK